The “2023 Glaucoma Pharmaceuticals Market Report” features new regional sales forecasts, market share analysis of generics and branded drugs by drug class in the United States, new analysis of pipeline products, and a summary of ongoing clinical trials. Also included is an updated analysis of the global and regional prevalence of glaucoma and the latest breakdown of diagnosis and treatment paradigms.
The report also features new survey data from the United States and Europe, including ophthalmologists’ preferences for sustained drug delivery.
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.